Breakthrough Cancer Pain

Oncology
2
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

LP
Lee's PharmaceuticalChina - Guangzhou
2 programs
1
1
Inhaled fentanyl aerosolPhase 21 trial
Inhaled fentanyl aerosolPhase 1/21 trial
Active Trials
NCT04713189Unknown96Est. Dec 2021
NCT05531422Completed60Est. Apr 2023
Takeda
TakedaTOKYO, Japan
1 program
Instanyl® Non-Interventional StudyN/A1 trial
Active Trials
NCT01045603Completed309Est. Apr 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Lee's PharmaceuticalInhaled fentanyl aerosol
Lee's PharmaceuticalInhaled fentanyl aerosol
TakedaInstanyl® Non-Interventional Study

Clinical Trials (3)

Total enrollment: 465 patients across 3 trials

NCT05531422Lee's PharmaceuticalInhaled fentanyl aerosol

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Start: Oct 2021Est. completion: Apr 202360 patients
Phase 2Completed
NCT04713189Lee's PharmaceuticalInhaled fentanyl aerosol

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain

Start: Mar 2021Est. completion: Dec 202196 patients
Phase 1/2Unknown
NCT01045603TakedaInstanyl® Non-Interventional Study

Instanyl® Non-Interventional Study

Start: Dec 2009Est. completion: Apr 2012309 patients
N/ACompleted

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space